Please follow this link to the  Pharmac consultation regarding improving access to treatments in the community for trauma and medical emergencies, and ketamine for palliative care. We want to make sure that everyone who needs to know about this proposal is aware of it. Please share this information with people you think might be interested. Ngā mihi Pharmac | Te Pātaka Whaioranga | P: +0800 660 050|  www.pharmac.govt.nz

Flumetasone pivalate (Locorten-Vioform) ear drops  (Pharmacode 259799) There may be some constrained supply as stock levels get low before the next shipment is released. But more stock should be available soon. FreeStyle Libre 3 Plus sensors: Recall  (Pharmacode: 2691655) There is a recall affecting some batches of the FreeStyle Libre 3 Plus sensors.  Levonorgestrel: The funded brand is changing  (Pharmacode: 2645424) The brand for the emergency contraceptive pill is changing

Kia ora,  Please follow this  link  to our website for the November 2025 Tender Notification. Ngā mihi, Stefanie Moir | Tender Analyst Te Pātaka Whaioranga | Pharmac | PO Box 10 254 | Level 9, 40 Mercer Street, Wellington | P: 0800 660 050 |  www.pharmac.govt.nz

From 1 March 2026 all HIV medicines will be able to be dispensed in three-month amounts, rather than monthly, making it easier for people to manage their treatment. In October, we consulted on three changes to the way New Zealanders access HIV medicines. Thank you to all those who provided feedback. In response to this feedback, we have delayed the proposed effective date from 1 December 2025 to 1 March 2026 to give everyone more time to adapt. We also decided not to remove

We are writing to inform you that Sanofi, the supplier of isoniazid 100mg with rifampicin 150mg ( Rifinah ) tab, has advised of a supply issue due to delays with manufacturing. The current stock has the expiry date 30 November 2025.    Key messages: An alternative brand Rifamazid  has been listed (funded) from 1 December 2025. This is an unapproved medicine and as such needs to be prescribed and dispensed in line with section 29 of the Medicines Act. It is estimated it will b

We want your feedback on a proposal to fund nitisinone for people with rare inherited metabolic disorders, including tyrosinemia type 1 and alkaptonuria. Nitisinone is currently funded through Pharmac’s Named Patient Pharmaceutical Assessment (NPPA) pathway. Under this proposal, it would be listed on the Pharmaceutical Schedule, making it easier for clinicians to prescribe and helping ensure ongoing supply in New Zealand. More information about the proposal is available here

This link  will take you to the proposal to enter into an agreement for sterilisation and decontamination equipment and associated consumable medical devices supplied by Steris New Zealand Limited (“Steris”). Steris’ range of medical devices are proposed to be listed on the Pharmaceutical Schedule under a Pharmac agreement from 1 February 2025. A list of products included in the proposal is attached .  Pharmac welcomes feedback on this proposal.  To provide feedback, please

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 21 November 2025. It includes information on:  New updates Resolved Supply Issues Pharmac funding both Estradot and Estradiol TDP Mylan brands of oestradiol patches From 1 December 2025, the funded brands of oestradiol patches will be Estradiol TDP Mylan and Estradot. Everyone who uses funded oestradiol patches will need to use either of these brand

New medicine supply notices Enalapril: Your brand is changing  The funded brand of enalapril is changing from Acetec to Ipca-Enalapril. It will be listed from 1 December 2025. It is the exact same product as supplied under the Ethics brand. Details and a patient flyer available on the website. Oxycodone oral liquid (Lucis)  (Pharmacode: 2678500) Following the oxycodone tablet supply issue, there is now limited stock of the oral liquid. An alternative brand, Rosemont (Pharmaco

This link  will take you to the notification of the decision to approve an agreement with Obex Medical Limited (“Obex”) for medical devices in the following categories:  •    adhesives, sealants, and haemostats •    feeding equipment and associated devices •    medical and surgical instruments and power tools  •    medical imaging, software, and associated products  •    patient assessment, monitoring, and treatment •    patient warming and cooling  •    sterilisation

Pharmac is seeking feedback on a proposal to fund another brand of methylphenidate - Rubifen LA - to help ease ongoing supply issues and provide more treatment options for people with attention deficit hyperactivity disorder (ADHD). If approved, this brand would be funded from 1 July 2026.   Proposal to fund a new brand of methylphenidate We welcome your feedback. Consultation is open until 5 pm, Thursday 4 December 2025. Please send your feedback to consult@pharmac.govt.nz  

Kia ora,Pharmac is seeking feedback on a proposal to fund another brand of methylphenidate - Rubifen LA - to help ease ongoing supply issues and provide more treatment options for people with attention deficit hyperactivity disorder (ADHD). If approved, this brand would be funded from 1 July 2026.   Proposal to fund a new brand of methylphenidate We welcome your feedback. Consultation is open until 5 pm, Thursday 4 December 2025. Please send your feedback to consult@pharmac.g

Kia ora   We are writing to inform you of a brand change.   Key Dates: Fulvestrant EVER Pharma brand of fulvestrant inj 50 mg per ml, 5 ml prefilled syringe will be listed (funded) on the Pharmaceutical Schedule from 1 December 2025. Fulvestrant EVER Pharma will be awarded Principal Supply Status (the main funded brand) from 1 May 2026 to 30 June 2028. The current brand Faslodex will be delisted (no longer funded) 1 May 2026.   Key Messages: Fulvestrant EVER Pharma is current

In this issue New medicine supply notices Paxlovid pharmacy-initiated supply Updated medicine supply notices Tender brand change for cefalexin Resolved issues Recent decisions or open consultations Monthly updates New medicine supply notices Fulvestrant: Your brand is changing  The funded brand of fulvestrant is changing from Faslodex to Fulvestrant EVER Pharma. Fulvestrant EVER Pharma will be listed from 1 December 2025. Faslodex will be delisted 1 May 2026. A patient flier

Kia ora,   This is a reminder following on from our notification in June regarding the change in funded brands of oestradiol patches.   From 1 December 2025, the funded brands of oestradiol patches will be Estradiol TDP Mylan and Estradot. Everyone who uses funded oestradiol patches will need to use either of these brands.   Pharmac has secured as much Estradot as the supplier can provide. However, there may be times when there is not enough Estradot for everyone who needs i

Below is the latest information on Pharmac consultations, notifications, and supply issues for Primary Care Prescribers for week 07 November 2025. It includes information on:  New updates Resolved Supply Issues Supply issue: codeine phosphate tab all strengths Noumed, the supplier of codeine phosphate tablets, has advised that the 30 mg presentation is currently out of stock. Limited stock remains of the 15 mg and 60 mg presentations. New stock will be available in the week c

Pharmac has confirmed it will fund silver diamine fluoride for people accessing dental services through public hospitals, and the ‘Health New Zealand Community Oral Health Service’ for children and some adolescents. This decision follows recent consultation and is expected to benefit children, elderly patients, and those who may find some traditional dental procedures challenging. Silver diamine fluoride is a topical dental treatment, combining ionic silver and fluoride. It

Kia ora   Brand Change: We are writing to inform you of the brand change for docusate sodium 50 mg with sennosides 8 mg tablet.   Key Messages: Solax a new brand of docusate sodium 50 mg with sennosides 8 mg, will be listed from 1 December 2025. The Laxsol brand will be delisted 1 May 2026. Please support your patients with this change. Although we do not anticipate problems, we are aware that the Laxsol brand has been available in NZ for many years. The Solax tablets and Lax

Pharmac Decision: Silver diamine fluoride to be funded from 1 December Pharmac has confirmed it will fund silver diamine fluoride for people accessing dental services through public hospitals, and the ‘Health New Zealand Community Oral Health Service’ for children and some adolescents. This decision follows recent consultation and is expected to benefit children, elderly patients, and those who may find some traditional dental procedures challenging. Silver diamine fluoride

Kia ora,Pharmac is funding five medicines through a multiproduct agreement with Roche. These medicines will provide new or improved treatment options for people with multiple sclerosis, eye conditions, breast cancer and lung cancer.The medicines we are funding are: Ocrelizumab (Ocrevus SC): a new injection option for multiple sclerosis Pertuzumab with trastuzumab (Phesgo): a new combined injection for HER2-positive metastatic breast cancer Faricimab (Vabysmo): for diabetic ma